Funding News

Sun Pharma's $11.75 Billion Organon Acquisition Gets Moody's Baa1 and S&P BBB+ Investment-Grade Ratings — And the Company Settled Its US Antitrust Case This Week

By Mustafa Shariff, Editor in Chief · September 16,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — Sun Pharma's $11.75 Billion Organon Acquisition Gets Moody's Baa1 and S&P BBB+ Investment-Grade Ratings — And the Company Settled Its US Antitrust Case This Week

Summary

  • Sun Pharma Gets Moody's Baa1 and S&P BBB+ for Organon Deal, Incorporates GIFT City Subsidiary, Settles US Antitrust Case — Q4 FY27 Close on Track
  • Sun Pharma received Moody's Baa1 (stable) and S&P BBB+ (stable) ratings reflecting the $11.75B Organon acquisition (September 8, 2026). Also incorporated a GIFT City treasury subsidiary and settled a US antitrust claim — all confirming Organon deal progress toward Q4 FY27 close.

"The investment-grade credit ratings from Moody's and S&P — both with stable outlook — reflect our confidence in the financial strength of the combined Sun Pharma-Organon entity. Sun Pharma enters the Organon acquisition as a company with strong free cash flow generation, a disciplined balance sheet, and a specialty medicine pipeline that reduces dependence on commodity generics. The Baa1 and BBB+ ratings confirm that global credit markets see the Organon transaction as strategically sound and financially manageable. We remain on track for a Q4 FY27 closing."

Sun Pharma's $11.75 billion acquisition of Organon & Co. — first covered in BHC Media's June 11 edition as the largest-ever overseas acquisition by an Indian pharmaceutical company — received investment-grade credit ratings from both Moody's (Baa1, stable outlook) and Standard & Poor's (BBB+, stable outlook) on September 8, 2026. Both ratings explicitly reflect Sun Pharma's combined credit profile incorporating the Organon acquisition.
What the Investment-Grade Ratings Mean
Moody's Baa1 and S&P BBB+ are both investment-grade ratings — the credit quality designation that makes a company's bonds eligible for purchase by institutional investors with investment-grade-only mandates, including pension funds, insurance companies, and sovereign wealth funds. For Sun Pharma, receiving investment-grade ratings from both major agencies for the combined Sun Pharma-Organon entity signals that global credit markets view the $11.75 billion transaction as financially manageable and strategically sound — not an overleveraged bet that threatens the combined entity's credit quality.
The stable outlook on both ratings indicates that neither agency anticipates a near-term credit quality change. This is significant because large pharmaceutical M&A transactions often attract negative credit outlooks during the integration period, reflecting leverage increase and execution risk. The stable outlooks on both Moody's Baa1 and S&P BBB+ suggest both agencies are satisfied with Sun Pharma's deleveraging trajectory and integration planning.
GIFT City Treasury Subsidiary
Sun Pharma incorporated a GIFT City treasury subsidiary on September 8, 2026, with an initial equity subscription of approximately Rs 9.50 crore. GIFT City (Gujarat International Finance Tec-City) is India's International Financial Services Centre — a special economic zone that allows Indian companies to conduct international financial activities (including foreign currency treasury management, offshore borrowing, and cross-border transactions) under a regulatory framework aligned with global financial centre standards rather than domestic Indian financial regulations.
A GIFT City treasury subsidiary for Sun Pharma is almost certainly connected to the Organon acquisition's financial architecture. A $11.75 billion transaction generates significant foreign currency flows — acquisition financing, foreign currency borrowings, ongoing Organon's revenue in multiple currencies, and the eventual integration of Organon's global cash flows into Sun Pharma's treasury. The GIFT City subsidiary provides an efficient regulatory framework for managing these international financial flows.
US Antitrust Settlement
On September 11, Sun Pharma announced that its subsidiaries have settled a US antitrust plaintiff claim for a confidential amount. US pharmaceutical antitrust litigation — typically relating to allegations of price-fixing or market allocation in generic drug markets — is a periodic feature of the legal landscape for large generic pharmaceutical companies operating in the United States. The settlement closes out this specific litigation without Sun Pharma disclosing the financial terms.
The Q4 FY27 Timeline
All three September developments confirm that Sun Pharma's Organon acquisition is progressing toward its previously stated Q4 FY27 (January-March 2027) closing timeline. Investment-grade credit ratings from both major agencies, a GIFT City treasury subsidiary for managing complex international financial flows, and settlement of legacy US litigation all represent the systematic preparation for the largest pharmaceutical transaction in India's history.
BHC Perspective
At Bengaluru Health Community, Sun Pharma's September cluster of corporate actions — credit ratings, GIFT City subsidiary, US antitrust settlement — is the detailed story behind the headline that the Organon deal is closing on schedule. For BHC founders in pharmaceutical business development and CDMO strategy — Sun Pharma's trajectory from India's largest generic pharmaceutical company to a globally diversified specialty pharma company through the Organon acquisition is the most consequential Indian pharmaceutical corporate event of the decade.
Frequently Asked Questions
Q: What ratings did Sun Pharma receive?
A: Moody's Baa1 (stable outlook) and S&P BBB+ (stable outlook) — both investment-grade, both explicitly reflecting the $11.75B Organon acquisition's impact on Sun Pharma's combined credit profile. Announced September 8, 2026.
Q: What is the GIFT City subsidiary for?
A: International treasury management for the Organon acquisition's complex foreign currency flows — acquisition financing, offshore borrowings, multi-currency Organon revenue integration. GIFT City's IFSC regulatory framework enables efficient cross-border financial operations under globally aligned standards.
Q: When is the Organon deal expected to close?
A: Q4 FY27 — January to March 2027. All three September developments (investment-grade ratings, GIFT City subsidiary, antitrust settlement) confirm the deal is on schedule.